Skip to main content

Biomarker innovations for critical conditions

Sometimes, in critically ill patients, the underlying pathomechanism behind the clinical symptoms is unclear. The research conducted at SphingoTec has identified key players involved in major pathways leading to mortality in critical care: bioactive Adrenomedullin (bio-ADM*) relevant for shock resulting from endothelial dysfunction, Proenkephalin A 119-159 (penKid*) preventing delayed recognition of loss of kidney function and Dipeptidyl Peptidase 3 (DPP3*) release resulting from dysregulated cell death. The innovative biomarkers allow for a better and faster understanding of the disease progression.

Body of evidence for our biomarkers:

Sepsis and Septic Shock

Acute Kidney Injury

Renal Transplantation

Chronic Kidney Disease

Cardiogenic Shock

Acute Heart Failure

Acute Myocardial Infarction

Acute Coronary Syndrome


Subarachnoid hemorrhage

Major Surgery


Discover more on the scientific evidence

SphingoTec biomarker discovery is based on the highest standard of evidence, with over 100 publications, over 100 clinical studies, and more than 100.000 patients enrolled. To discover more on our scientific research, visit our publications page. 

Learn more


Sphingotest® penKid®, and sphingotest® bio-ADM® are offered for in vitro diagnostics. “penKid” and “bio-ADM” represent the analytes Proenkephalin A 119-159 and bioactive Adrenomedullin 1-52, respectively.